Novartis Ag

Novartis Pharmaceuticals Corporation

Schering Aktiengesellschaft

Other

Ciba Vision Corporation

Novartis Pharma Ag

Novartis Pharma Gmbh

Novartis International Pharmaceutical Ag

Jeanette Marjorie Wood

Guido Bold

Paul William Manley

Karl-Heinz Altmann

Pascal Furet

Andreas Huth

Dieter Seidelmann

Karl-Heinz Thierauch

Andreas Menrad

Terence O'Reilly

Heidi Lane

J&ouml;rg Frei

Stefano Ferrari

Martin Haberey

Peter Traxler

Bernhard Wietfeld

Jürgen Mestan

Martin Krüger

Richard Heng

David Raymond Stover

Janet Dawson King

Francesco Hofmann

Helmut Mett

Terence O'reilly

Peter Anthony Campochiaro

Markus Wartmann

Romulus Kimbro Brazzell

John David Rothermel

Eckhard Ottow

Michael Schirner

Volker Brinkmann

Frances Elizabeth Kane

Martin Kr&uuml;ger

TianLing Chen

Diane Greeley

J&uuml;rgen Mestan

Joerg Frei

Thomas Baumruker

Jose Brüggen

Jörg Frei

Kenneth Richard La Montagne

Peter T Lassota

Terence O`Reilly

Diana Mechtcheriakova

The present invention is directed to the use of rapamycin derivatives for use in treating solid tumors, optionally in combination with a chemotherapeutic agent.

Treatment of solid tumors with rapamycin derivatives

Rapamycin derivatives have interesting effects in the treatment of solid tumours, optionally in combination with a chemotherapeutic agent.

Rapamycin derivatives have interesting effects in the treatment of solid tumors, optionally in combination with a chemotherapeutic agent.

Cancer treatment

The invention relates to a combination which comprises (a) a bisphosphonate, a platinum compound or a vasculostatic compound and (b) an epothilone derivative of formula I wherein A represents O or NR, wherein Ris hydrogen or lower alkyl, R is hydrogen or lower alkyl, and Z is O or a bond, in which the active ingredients (a) and (b) are present in each case in free form or in the form of a pharmaceutically acceptable salt and optionally at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use, in particular for the delay of progression or treatment of a proliferative disease, especially a solid tumor disease; a pharmaceutical composition, a commercial package or product comprising such a combination; the use of such a combination for the preparation of a medicament for the delay of progression or treatment of a proliferative disease and to a method of treatment of a warm-blooded animal.

Combinations comprising epothilones and pharmaceutical uses thereof

The invention relates to the treatment of leukemias with an inhibitor of the activity of VEGF receptor tyrosine kinase of the formula I, 

Phthalazine derivatives for treating inflammatory diseases

The invention relates to anthranilic acid amides and the use thereof as medicaments for the treatment of diseases that are triggered by persistent angiogenesis, in addition to intermediate products in the production of anthranilic acid amides.

Anthranilic acid amides and the use thereof as medicaments

Described are compunds of formula (I), wherein W is O or S; X is NR; Y is CRR&#x2014;(CH)n wherein Rand Rare independently of each other hydrogen or lower alkyl, and n is an integer of from and including 0 to and including 3; or Y is SO; Ris aryl; Ris a mono- or bicyclic heteroaryl group comprising one or more ring nitrogen atoms with the exception that Rcannot represent 2-phthalimidyl, and in case of Y=SOcannot represent 2,1,3-benzothiadiazol-4-yl; any of R, R, Rand R, independently of the other, is H or a substituent other than hydrogen; and Rand R, independently of each other, are H or lower alkyl; or a N-oxide or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical product for the treatment of a neoplastic disease which responds to an inhibition of the VEGF receptor tyrosine kinase activity. The compounds of formula (I) can be used for the treatment e.g. of a neoplastic disease, such as a tumor disease, of retinopathy and age-related macular degeneration.

N-Aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF

The invention relates to the treatment of an inflammatory disease, especially an inflammatory rheumatoid or rheumatic disease, and/or pain with an inhibitor of the activity of VEGF receptor tyrosine kinase of the formula I,

Described are compunds of formula (I), wherein W is O or S; X is NR; Y is CRR&#x2014;(CH)n wherein Rand Rare independently of each other hydrogen or lower alkyl, and n is an integer of from and including 0 to and including 3; or Y is SO; Ris aryl; Ris a bicyclic heteroaryl group comprising one ring nitrogen atom with the exception that Rcannot represent 2-phthalimidyl; any of R, R, Rand R, independently of the other, is H or a substituent other than hydrogen; and Rand R, independently of each other, are H or lower alkyl; or a N-oxide or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical product for the treatment of a neoplastic disease which responds to an inhibition of the VEGF receptor tyrosine kinase activity. The compounds of formula (I) can be used for the treatment e.g. of a neoplastic disease, such as a tumor disease, of retinopathy and age-related macular degeneration.

VEGF receptor tyrosine kinase inhibitors

Phthalazines with angiogenesis inhibiting activity

Pyrido-, pyrimido-, pyridazo- and pyrazo- pyridazines having angiogenesis inhibiting activity

Described are compounds of formula (I), wherein W is O or S; X is NR ; Y is CR R &mdash;(CH )n wherein R and R are independently of each other hydrogen or lower alkyl, and n is an integer of from and including 0 to and including 3; or Y is S0 ; R is aryl; R is a mono- or bicyclic heteroaryl group comprising one or more ring nitrogen atoms with the exception that R cannot represent 2-phthalimidyl, and in case of Y&equals;SO cannot represent 2,1,3-benzothiadiazol-4-yl; any of R , R , R and R , independently of the other, is H or a substituent other than hydrogen; and R and R , independently of each other, are H or lower alkyl; or a N-oxide or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical product for the treatment of a neoplastic disease which responds to an inhibition of the VEGF receptor tyrosine kinase activity. The compounds of formula (I) can be used for the treatment e.g. of a neoplastic disease, such as a tumor disease, of retinopathy and age-related macular degeneration.

Growing community of inventors

Biel-Benken, Switzerland

Jeanette Marjorie Wood